EGFR and colorectal carcinoma: Numerous studies have demonstrated that overexpression of EGFR and alteration of signaling pathways could trigger and/or accelerate the progression of CRC, which assists in the treatment against EGFR using monoclonal antibodies (e.g., cetuximab and panitumumab) in CRC-targeted therapies.